Ontology highlight
ABSTRACT:
SUBMITTER: Balakirouchenane D
PROVIDER: S-EPMC7226106 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
Balakirouchenane David D Guégan Sarah S Csajka Chantal C Jouinot Anne A Heidelberger Valentine V Puszkiel Alicja A Zehou Ouidad O Khoudour Nihel N Courlet Perrine P Kramkimel Nora N Lheure Coralie C Franck Nathalie N Huillard Olivier O Arrondeau Jennifer J Vidal Michel M Goldwasser Francois F Maubec Eve E Dupin Nicolas N Aractingi Selim S Guidi Monia M Blanchet Benoit B
Cancers 20200409 4
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure-response relationship for toxicity and efficacy in metastatic melanoma (MM) patients. Univariate Fisher and Wilcoxon models including drug systemic exposure (area under the plasma concentration curve, AUC) were used ...[more]